{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:41:32Z","timestamp":1791726092951,"version":"4.3.4"},"reference-count":141,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 8754\/1-1"],"award-info":[{"award-number":["HA 8754\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jhepr.2021.100226","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T01:12:46Z","timestamp":1611018766000},"page":"100226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Cell of origin in biliary tract cancers and clinical implications"],"prefix":"10.1016","volume":"3","author":[{"given":"Agrin","family":"Moeini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp K.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100226_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma-evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2021.100226_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100226_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib8","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100226_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib10","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100226_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2021.100226_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1158\/0008-5472.CAN-14-1428","article-title":"Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes","volume":"75","author":"Robertson-Tessi","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2006.09.042","article-title":"Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment","volume":"127","author":"Anderson","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100226_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature09781","article-title":"Cells of origin in cancer","volume":"469","author":"Visvader","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2021.100226_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nature07602","article-title":"Crypt stem cells as the cells-of-origin of intestinal cancer","volume":"457","author":"Barker","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature07589","article-title":"Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation","volume":"457","author":"Zhu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib28","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0913873107","article-title":"Basal epithelial stem cells are efficient targets for prostate cancer initiation","volume":"107","author":"Lawson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100226_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100226_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/75596","article-title":"Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice","volume":"25","author":"Holland","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100226_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2008.12.006","article-title":"Malignant astrocytomas originate from neural stem\/progenitor cells in a somatic tumor suppressor mouse model","volume":"15","author":"Alcantara Llaguno","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2007.06.013","article-title":"Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes","volume":"12","author":"Ince","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib34","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100226_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2017.08.017","article-title":"Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers","volume":"16","author":"Torre","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","article-title":"Changing international trends in mortality rates for liver, biliary and pancreatic tumours","volume":"37","author":"Khan","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100226_bib38","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2:10","author":"Patel","year":"2002","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mds652","article-title":"A\u00a0comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe","volume":"24","author":"Bertuccio","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2021.100226_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib42","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"10.1016\/j.jhepr.2021.100226_bib43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4254\/wjh.v2.i12.419","article-title":"Pathological classification of intrahepatic cholangiocarcinoma based on a new concept","volume":"2","author":"Nakanuma","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/hbsn.2016.11.04","article-title":"Pathology of intrahepatic cholangiocarcinoma","volume":"6","author":"Vijgen","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhepr.2021.100226_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100226_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00535-013-0810-5","article-title":"Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia","volume":"49","author":"Sato","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100226_bib47","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2021.100226_bib48","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/hep.25595","article-title":"Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes","volume":"55","author":"Komuta","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib49","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ajpath.2015.02.010","article-title":"Profiles of cancer stem cell subpopulations in cholangiocarcinomas","volume":"185","author":"Cardinale","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2021.100226_bib50","first-page":"42","article-title":"New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin","volume":"31","author":"Bragazzi","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100226_bib51","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.29789","article-title":"cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation","volume":"68","author":"Brunt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib54","series-title":"WHO Classif. tumours Dig. Syst","first-page":"225","article-title":"Combined hepatocellular-cholangiocarcinoma","author":"Theise","year":"2010"},{"key":"10.1016\/j.jhepr.2021.100226_bib55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","article-title":"Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity","author":"Moeini","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/liv.12563","article-title":"Clinicopathological significance of \u201csubtypes with stem-cell feature\u201d in combined hepatocellular-cholangiocarcinoma","volume":"35","author":"Sasaki","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100226_bib57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm1377","article-title":"A\u00a0novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells","volume":"12","author":"Lee","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2021.100226_bib58","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/hep.22238","article-title":"Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin","volume":"47","author":"Komuta","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib59","series-title":"World Health Organization Classification of Tumours","first-page":"266","article-title":"Carcinoma of the gallbladder and extrahepatic bile ducts","author":"Albores-Saavedra","year":"2010"},{"key":"10.1016\/j.jhepr.2021.100226_bib60","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jhepr.2021.100226_bib61","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2015.06.018","article-title":"Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis","volume":"63","author":"Carpino","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib62","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.26485","article-title":"Identification of intramural epithelial networks linked to peribiliary glands that express progenitor cell markers and proliferate after injury in mice","volume":"58","author":"Dipaola","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/hep.28326","article-title":"The hepatic, biliary, and pancreatic network of stem\/progenitor cell niches in humans: a new reference frame for disease and regeneration","volume":"64","author":"Lanzoni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jcp.2005.033712","article-title":"Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes","volume":"59","author":"Hughes","year":"2006","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jhepr.2021.100226_bib65","series-title":"Digestive System Tumours: WHO Classification of Tumours (Medicine)","year":"2019"},{"key":"10.1016\/j.jhepr.2021.100226_bib66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000286463","article-title":"Embryology of the biliary tract","volume":"27","author":"Ando","year":"2010","journal-title":"Dig Surg"},{"key":"10.1016\/j.jhepr.2021.100226_bib67","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jhep.2014.01.026","article-title":"Evidence for multipotent endodermal stem\/progenitor cell populations in human gallbladder","volume":"60","author":"Carpino","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib68","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib69","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib71","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib72","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1186\/s12885-019-6320-y","article-title":"HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis","volume":"19","author":"Albrecht","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib73","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.25890","article-title":"Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma","volume":"56","author":"Oishi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib74","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","article-title":"EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features","volume":"136","author":"Yamashita","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib75","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib76","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1053\/hupa.2000.9782","article-title":"Genetic classification of combined hepatocellular-cholangiocarcinoma","volume":"31","author":"Fujii","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhepr.2021.100226_bib78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib79","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/carcin\/bgs208","article-title":"Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGF\u03b2 signaling pathways","volume":"33","author":"Coulouarn","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhepr.2021.100226_bib80","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2021.100226_bib81","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/hep.20214","article-title":"Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells","volume":"39","author":"Fausto","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib82","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.20969","article-title":"Liver regeneration","volume":"43","author":"Fausto","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.gastro.2009.05.044","article-title":"Stem cells and liver regeneration","volume":"137","author":"Duncan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.stem.2014.04.010","article-title":"Stem\/progenitor cells in liver development, homeostasis, regeneration, and reprogramming","volume":"14","author":"Miyajima","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib85","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.celrep.2014.07.003","article-title":"Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury","volume":"8","author":"Schaub","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2021.100226_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.stem.2014.09.008","article-title":"Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes","volume":"15","author":"Tarlow","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib87","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1101\/gad.207803.112","article-title":"Robust cellular reprogramming occurs spontaneously during liver regeneration","volume":"27","author":"Yanger","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhepr.2021.100226_bib88","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1172\/JCI77995","article-title":"Hepatocellular carcinoma originates from hepatocytes and not from the progenitor\/biliary compartment","volume":"125","author":"Mu","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100226_bib89","first-page":"973","article-title":"Hepatic progenitor cells of biliary origin with liver repopulation capacity","volume":"17","author":"Lu","year":"2015","journal-title":"Nat Cel Biol"},{"key":"10.1016\/j.jhepr.2021.100226_bib90","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature23015","article-title":"Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration","volume":"547","author":"Raven","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2018.05.022","article-title":"Chronic liver injury induces conversion of biliary epithelial cells into hepatocytes","volume":"23","author":"Deng","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib92","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.30340","article-title":"Cellular plasticity in liver regeneration: spotlight on cholangiocytes","volume":"69","author":"Tirnitz-Parker","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V","article-title":"DNA excision in liver by an albumin-Cre transgene occurs progressively with age","volume":"26","author":"Postic","year":"2000","journal-title":"Genesis"},{"key":"10.1016\/j.jhepr.2021.100226_bib94","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI27282","article-title":"Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice","volume":"116","author":"Xu","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100226_bib95","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/nprot.2007.471","article-title":"Preferential delivery of the sleeping beauty transposon system to livers of mice by hydrodynamic injection","volume":"2","author":"Bell","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jhepr.2021.100226_bib96","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1172\/JCI63065","article-title":"Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes","volume":"122","author":"Sekiya","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100226_bib97","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ccr.2013.04.019","article-title":"A\u00a0critical role for notch signaling in the formation of cholangiocellular carcinomas","volume":"23","author":"Zender","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib98","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1172\/JCI63212","article-title":"Cholangiocarcinomas can originate from hepatocytes in mice","volume":"122","author":"Fan","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100226_bib99","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1038\/oncsis.2016.73","article-title":"Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans","volume":"5","author":"Che","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jhepr.2021.100226_bib100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41419-017-0183-4","article-title":"Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model","volume":"9","author":"Dong","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2021.100226_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077433","article-title":"Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in\u00a0vivo","volume":"8","author":"El Khatib","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2021.100226_bib102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","author":"Seehawer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100226_bib103","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.1073\/pnas.1600067113","article-title":"Notch3 drives development and progression of cholangiocarcinoma","volume":"113","author":"Guest","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100226_bib104","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O\u2019Dell","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1053\/j.gastro.2015.11.039","article-title":"Epithelial transforming growth factor-\u03b2 signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma","volume":"150","author":"Mu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib106","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1158\/0008-5472.CAN-17-1123","article-title":"Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma","volume":"78","author":"Hill","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib107","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1038\/srep23899","article-title":"A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion","volume":"6","author":"Ikenoue","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100226_bib108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.02.017","article-title":"Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy","volume":"421","author":"Lin","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2021.100226_bib109","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib110","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1073\/pnas.0911427107","article-title":"Hippo signaling is a potent in\u00a0vivo growth and tumor suppressor pathway in the mammalian liver","volume":"107","author":"Lu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100226_bib111","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","article-title":"Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice","volume":"67","author":"Zhang","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib112","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.1938710","article-title":"Nf2\/Merlin controls progenitor homeostasis and tumorigenesis in the liver","volume":"24","author":"Benhamouche","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhepr.2021.100226_bib113","doi-asserted-by":"crossref","first-page":"10102","DOI":"10.18632\/oncotarget.3546","article-title":"Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2021.100226_bib114","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2013.03.013","article-title":"Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types","volume":"145","author":"Holczbauer","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2007.06.016","article-title":"Enhanced self-renewal capability in hepatic stem\/progenitor cells drives cancer initiation","volume":"133","author":"Chiba","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100226_bib116","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ar.20710","article-title":"Embryology of extra- and intrahepatic bile ducts, the ductal plate","volume":"291","author":"Roskams","year":"2008","journal-title":"Anat Rec"},{"key":"10.1016\/j.jhepr.2021.100226_bib117","first-page":"6971","article-title":"Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma","volume":"61","author":"Kiguchi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100226_bib118","doi-asserted-by":"crossref","first-page":"E3806","DOI":"10.1073\/pnas.1619416114","article-title":"Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands","volume":"114","author":"Nakagawa","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100226_bib119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18632\/oncoscience.368","article-title":"KrasG12D upregulates notch signaling to induce gallbladder tumorigenesis in mice","volume":"4","author":"Chung","year":"2017","journal-title":"Oncoscience"},{"key":"10.1016\/j.jhepr.2021.100226_bib120","doi-asserted-by":"crossref","first-page":"14763","DOI":"10.1073\/pnas.1009483107","article-title":"Estrogen-dependent gallbladder carcinogenesis in LXR\u03b2-\/- female mice","volume":"107","author":"Gabbi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100226_bib121","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib122","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib123","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/hep.27268","article-title":"Emerging roles of Notch signaling in liver disease","volume":"61","author":"Geisler","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100226_bib124","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","article-title":"Wnt\u2013\u03b2-catenin signalling in liver development, health and disease","volume":"16","author":"Perugorria","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib125","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","article-title":"Hippo pathway activity influences liver cell fate","volume":"157","author":"Yimlamai","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib126","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1172\/JCI45976","article-title":"The cautionary tale of side effects of chronic Notch1 inhibition","volume":"121","author":"Ryeom","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100226_bib127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhepr.2021.100226_bib128","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2021.100226_bib129","first-page":"564","article-title":"Phase i study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","volume":"8","author":"Yoo","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A\u00a0phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhepr.2021.100226_bib131","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100226_bib132","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00534-012-0542-6","article-title":"Recent advances in cancer stem cell research for cholangiocarcinoma","volume":"19","author":"Kokuryo","year":"2012","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhepr.2021.100226_bib133","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jhep.2014.09.007","article-title":"Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts","volume":"62","author":"Raggi","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib134","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4017","article-title":"ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations","volume":"35","author":"Mazzaferro","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib136","doi-asserted-by":"crossref","first-page":"ix49","DOI":"10.1093\/annonc\/mdy432.007","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi\u2019s","volume":"29","author":"Tran","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial","volume":"37","author":"Wainberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100226_bib138","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100226_bib139","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cell.2014.05.051","article-title":"P53-dependent nestin regulation links tumor suppression to cellular plasticity in liver cancer","volume":"158","author":"Tschaharganeh","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2021.100226_bib140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/path.4189","article-title":"PTEN loss and KRAS activation cooperate in murine biliary tract malignancies","volume":"230","author":"Marsh","year":"2013","journal-title":"J\u00a0Pathol"},{"issue":"Suppl. 4","key":"10.1016\/j.jhepr.2021.100226_bib141","doi-asserted-by":"crossref","first-page":"iv127","DOI":"10.1093\/annonc\/mdz154.004","article-title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT \u2018basket\u2019 trial","volume":"30","author":"Harding","year":"2019","journal-title":"Ann Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:42Z","timestamp":1762899942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2589555921000021"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100226","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell of origin in biliary tract cancers and clinical implications","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100226"}}